Posted inMarket
Baird Raises DocuSign Stock Price Target Following Strong ARR Growth
Financial firm Baird has increased DocuSign stock price target to $72 following solid annual recurring revenue growth.
Posted inMarket
Baird Increases Climb Bio Stock Price Target Following Trial Data
Financial firm Baird has raised its price target for Climb Bio stock to $25 following recent clinical trial data updates.
